We apologize for Proteopedia being slow to respond. For the past two years, a new implementation of Proteopedia has been being built. Soon, it will replace this 18-year old system. All existing content will be moved to the new system at a date that will be announced here.

2p4y

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2p4y.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2p4y.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2p4y| PDB=2p4y | SCENE= }}
{{STRUCTURE_2p4y| PDB=2p4y | SCENE= }}
-
'''Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator'''
+
===Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator===
-
==Overview==
+
<!--
-
Despite their proven antidiabetic efficacy, widespread use of peroxisome proliferator-activated receptor (PPAR)gamma agonists has been limited by adverse cardiovascular effects. To overcome this shortcoming, selective PPARgamma modulators (SPPARgammaMs) have been identified that have antidiabetic efficacy comparable with full agonists with improved tolerability in preclinical species. The results of structural studies support the proposition that SPPARgammaMs interact with PPARgamma differently from full agonists, thereby providing a physical basis for their novel activities. Herein, we describe a novel PPARgamma ligand, SPPARgammaM2. This compound was a partial agonist in a cell-based transcriptional activity assay, with diminished adipogenic activity and an attenuated gene signature in cultured human adipocytes. X-ray cocrystallography studies demonstrated that, unlike rosiglitazone, SPPARgammaM2 did not interact with the Tyr473 residue located within helix 12 of the ligand binding domain (LBD). Instead, SPPARgammaM2 was found to bind to and activate human PPARgamma in which the Tyr473 residue had been mutated to alanine (hPPARgammaY473A), with potencies similar to those observed with the wild-type receptor (hPPARgammaWT). In additional studies, we found that the intrinsic binding and functional potencies of structurally distinct SPPARgammaMs were not diminished by the Y473A mutation, whereas those of various thiazolidinedione (TZD) and non-TZD PPARgamma full agonists were reduced in a correlative manner. These results directly demonstrate the important role of Tyr473 in mediating the interaction of full agonists but not SPPARgammaMs with the PPARgamma LBD, thereby providing a precise molecular determinant for their differing pharmacologies.
+
The line below this paragraph, {{ABSTRACT_PUBMED_17940191}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 17940191 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_17940191}}
==About this Structure==
==About this Structure==
Line 31: Line 35:
[[Category: Sppargm]]
[[Category: Sppargm]]
[[Category: Transcription]]
[[Category: Transcription]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 12:22:24 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 02:43:19 2008''

Revision as of 23:43, 27 July 2008

Image:2p4y.png

Template:STRUCTURE 2p4y

Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator

Template:ABSTRACT PUBMED 17940191

About this Structure

2P4Y is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities., Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley RT, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP, Mol Pharmacol. 2008 Jan;73(1):62-74. Epub 2007 Oct 16. PMID:17940191

Page seeded by OCA on Mon Jul 28 02:43:19 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2p4y"
Personal tools